Home > Healthcare > Drug Device Combination > Drug Filled Devices > U.S. Hormone Replacement Therapy Market

U.S. Hormone Replacement Therapy Market Size

  • Report ID: GMI7407
  • Published Date: Nov 2023
  • Report Format: PDF

U.S. Hormone Replacement Therapy Market Size

The U.S. Hormone Replacement Therapy Market size in 2022 was evaluated to be USD 6.9 billion and is anticipated to be valued at USD 13.4 billion by 2032. The aging U.S. population, with a significant number of women reaching menopausal stages, is a primary driver of the HRT market. As people age, there is an increased prevalence of hormonal imbalances and associated symptoms, resulting in a heightened demand for hormone replacement therapies.

 

U.S. Hormone Replacement Therapy Market

To understand key trends  
Download Free Sample
 

Furthermore, rising cases of thyroid disorders and other endocrine disorders is aiding the market progress. For instance, as per a study published by NIH, in 2022, prevalence of hypothyroidism (HT) was approximately 4.6% in the U.S. population. Additionally, with a surge in the number of specialized clinics and healthcare providers offering HRT coupled with a paradigm shift towards personalized and preventative healthcare in the market is poised to witness high growth.

 

 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

U.S. hormone replacement therapy industry size was USD 6.9 billion in 2022 and is anticipated to be valued at USD 13.4 billion from 2023-2032 due to the aging population and the significant number of women reaching menopausal stages.

The oral route of administration recorded 43.5% share of the market in 2022 driven by non-invasive nature, precise and consistent drug dosing, affordability, and the strong preference of patients.

The hospital pharmacies distribution channel segment held 57.2% of the U.S. hormone replacement therapy market share in 2022 due to the presence of the highest quality of care.

Some of the major hormone replacement therapy firms in the U.S. include Eli Lilly and Company, Bayer AG, Pfizer Inc., Viatris, Inc., Noven Pharmaceuticals, Inc., Merck KGaA, Novo Nordisk A/S, and F. Hoffmann-La Roche Ltd.

U.S. Hormone Replacement Therapy Market Scope

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 12
  • Tables & Figures: 60
  • Countries covered: 1
  • Pages: 91
 Download Free Sample